Molecular Targeted Cancer Therapies and the Kidney

Novel, targeted anticancer therapies have increased survival rates in patients. However, the incidence, severity, and pattern of their toxicities are different from those of traditional chemotherapies. The high prevalence of chronic kidney disease in the general population and the increased incidence of cancer highlight the need for nephrology consultation regarding this issue. Here, we review the incidence, mechanisms, and management of adverse renal effects associated with major molecular, targeted cancer therapies. Early diagnosis and prompt intervention in case of adverse renal events are crucial for the proper management of patients with cancer treated with targeted agents.

Cite this article as: Baş Aksu Ö, Eren Sadioğlu R, Şengül Ş. Molecular Targeted Cancer Therapies and the Kidney. Turk J Nephrol 2020; 29(3): 232-41.